These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30610681)

  • 1. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):229-235. PubMed ID: 30610681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J; Holmes MV; Preiss D
    J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein (CETP) inhibitors.
    Hunt JA; Lu Z
    Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
    Kleber ME; Grammer TB; März W
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():47-55. PubMed ID: 21591319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anacetrapib as a potential cardioprotective strategy.
    Di Bartolo BA; Nicholls SJ
    Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of CETP inhibitors: a patent review.
    Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
    Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and biophysical insight into cholesteryl ester-transfer protein.
    Hall J; Qiu X
    Biochem Soc Trans; 2011 Aug; 39(4):1000-5. PubMed ID: 21787337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
    Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evacetrapib.
    Nicholls SJ
    Curr Cardiol Rep; 2012 Jun; 14(3):245-50. PubMed ID: 22362199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.
    Bell TA; Graham MJ; Lee RG; Mullick AE; Fu W; Norris D; Crooke RM
    J Lipid Res; 2013 Oct; 54(10):2647-57. PubMed ID: 23801661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with cholesteryl ester transfer protein inhibitors.
    Di Bartolo BA; Duong M; Nicholls SJ
    Curr Opin Lipidol; 2016 Dec; 27(6):545-549. PubMed ID: 27676199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New horizons for cholesterol ester transfer protein inhibitors.
    Schwartz GG
    Curr Atheroscler Rep; 2012 Feb; 14(1):41-8. PubMed ID: 22083134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.